ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 05/31/22

Zentalis Pharmaceuticals (NASDAQ:ZNTL) promotes cofounder Cam Gallagher to President and will report to CEO Dr. Kimberly Blackwell.  Mr. Gallagher, who previously served as an executive Director of the company, will remain a member of the Board of Directors, which he ...

NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the prom...

NEW YORK and SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the clos...

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30 years, researchers have been looking into the potenti...

Clinical-stage biotech Zentalis Pharmaceuticals (NASDAQ:ZNTL) on Monday appointed board member Kimberly Blackwell as its CEO, replacing Anthony Sun. Before joining ZNTL, Blackwell was chief medical officer at Tempus, a privately held data-providing precision medicine company. She was a vice p...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) priced its underwritten offering of 10.3M shares at an offering price of $19.38/share for total gross proceeds of ~$200.2M. Offer is expected to close on May 18. Net proceeds to be used for funding ongoing and planned clinical trials, incl...

NEW YORK and SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pric...

Dave Johnson appointed as Chairman of the Board Anthony Sun, MD, former CEO of Zentalis, to remain CEO of joint venture, Zentera Therapeutics NEW YORK and SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmac...

Zentalis Pharmaceuticals press release (NASDAQ:ZNTL): Q1 GAAP EPS of -$1.31 misses by $0.10. The company believes that its existing cash, cash equivalents and marketable securities of 4289.4M as of March 31, 2022, together with approximately $24.7M of net proceeds from the April 2022 Pfizer e...

Announced initial data on ZN-c3 in combination with chemotherapy in advanced ovarian cancer and interim data on ZN-c3 in uterine serous carcinoma (USC) at AACR Received a $25 million equity investment from Pfizer, with plans to jointly advance clinical development of ZN-c3, and ...